3D Medicines Inc. Initiates First Human Trial for Novel Radioactive Drug Conjugate 3D1015 Targeting Prostate Cancer

Reuters

2025/08/28

<a href="https://laohu8.com/S/01244">3D Medicines</a> Inc. Initiates First Human Trial for Novel Radioactive Drug Conjugate 3D1015 Targeting Prostate Cancer

3D Medicines Inc. has announced the successful administration of the first dose in humans for their novel radioactive drug conjugate 3D1015, referred to as 177Lu-PSMA-3D1015. This development is part of a clinical study aimed at evaluating the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), a group with significant unmet clinical needs. The trial will focus on assessing the drug's safety profile, radiation dosimetry, and collecting extensive pharmacokinetic data and dose-exploration findings. These results will offer critical clinical evidence needed for determining dosage and managing risks in future registrational clinical trials. The company has not yet presented results from this study and advises shareholders and potential investors to exercise caution when dealing with the company's shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3D Medicines Inc. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2562380084"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562380084\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562380084?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 17:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562380084","market":"us","top_or_hot":-1,"title":"3D Medicines Inc. Initiates First Human Trial for Novel Radioactive Drug Conjugate 3D1015 Targeting Prostate Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/01244\">3D Medicines</a> Inc. Initiates First Human Trial for Novel Radioactive Drug Conjugate 3D1015 Targeting Prostate Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        3D Medicines Inc. has announced the successful administration of the first dose in humans for their novel radioactive drug conjugate 3D1015, referred to as 177Lu-PSMA-3D1015. This development is part of a clinical study aimed at evaluating the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), a group with significant unmet clinical needs. The trial will focus on assessing the drug's safety profile, radiation dosimetry, and collecting extensive pharmacokinetic data and dose-exploration findings. These results will offer critical clinical evidence needed for determining dosage and managing risks in future registrational clinical trials. The company has not yet presented results from this study and advises shareholders and potential investors to exercise caution when dealing with the company's shares.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3D Medicines Inc. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3D Medicines Inc. Initiates First Human Trial for Novel Radioactive Drug Conjugate 3D1015 Targeting Prostate Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3D Medicines Inc. Initiates First Human Trial for Novel Radioactive Drug Conjugate 3D1015 Targeting Prostate Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-28 17:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/01244\">3D Medicines</a> Inc. Initiates First Human Trial for Novel Radioactive Drug Conjugate 3D1015 Targeting Prostate Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        3D Medicines Inc. has announced the successful administration of the first dose in humans for their novel radioactive drug conjugate 3D1015, referred to as 177Lu-PSMA-3D1015. This development is part of a clinical study aimed at evaluating the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), a group with significant unmet clinical needs. The trial will focus on assessing the drug's safety profile, radiation dosimetry, and collecting extensive pharmacokinetic data and dose-exploration findings. These results will offer critical clinical evidence needed for determining dosage and managing risks in future registrational clinical trials. The company has not yet presented results from this study and advises shareholders and potential investors to exercise caution when dealing with the company's shares.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3D Medicines Inc. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDLbmC37:1","article_id":"2562380084","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562380084","pubTimestamp":1756372483,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"3D Medicines Inc. has announced the successful administration of the first dose in humans for their novel radioactive drug conjugate 3D1015, referred to as 177Lu-PSMA-3D1015. This development is part of a clinical study aimed at evaluating the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer , a group with significant unmet clinical needs. The trial will focus on assessing the drug's safety profile, radiation dosimetry, and collecting extensive pharmacokinetic data and dose-exploration findings. These results will offer critical clinical evidence needed for determining dosage and managing risks in future registrational clinical trials. The company has not yet presented results from this study and advises shareholders and potential investors to exercise caution when dealing with the company's shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01244":"思路迪医药股份"},"translate_title":"3D Medicines Inc.启动针对前列腺癌的新型放射性药物偶联物3D1015的首次人体试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01244":0.9},"content_text":"3D Medicines Inc. Initiates First Human Trial for Novel Radioactive Drug Conjugate 3D1015 Targeting Prostate Cancer\n    \n\n        3D Medicines Inc. has announced the successful administration of the first dose in humans for their novel radioactive drug conjugate 3D1015, referred to as 177Lu-PSMA-3D1015. This development is part of a clinical study aimed at evaluating the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), a group with significant unmet clinical needs. The trial will focus on assessing the drug's safety profile, radiation dosimetry, and collecting extensive pharmacokinetic data and dose-exploration findings. These results will offer critical clinical evidence needed for determining dosage and managing risks in future registrational clinical trials. The company has not yet presented results from this study and advises shareholders and potential investors to exercise caution when dealing with the company's shares.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3D Medicines Inc. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}